Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report) shares rose 7.8% on Friday . The company traded as high as $0.20 and last traded at $0.19. Approximately 19,100 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Stock Performance
The stock has a fifty day simple moving average of $0.19 and a two-hundred day simple moving average of $0.19. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 2.86.
Vyant Bio Company Profile
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
See Also
- Five stocks we like better than Vyant Bio
- Find and Profitably Trade Stocks at 52-Week Lows
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 ETFs to Ride the VIX Surge During Market Volatility
- What is a Stock Market Index and How Do You Use Them?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
